Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017
Published Date: 2/5/2026
Rule
Summary
Starting March 9, 2026, emergency medical services (EMS) agencies must register under new rules that make it easier and safer to handle emergency medicines like controlled substances. These changes let EMS pros give important meds without a doctor right there, while keeping better track of storage and delivery. This update affects EMS agencies nationwide and helps patients get faster, safer care without extra costs.
Analyzed Economic Effects
6 provisions identified: 4 benefits, 0 costs, 2 mixed.
EMS Can Administer Controlled Drugs Without Doctor Present
Starting March 9, 2026, emergency medical services professionals of a registered EMS agency may administer controlled substances in Schedules II–V outside the physical presence of a medical director if State law allows and the administration is done pursuant to valid standing or verbal orders. This change is intended to let EMS personnel give needed emergency medicines more quickly at the scene or during transport.
New State-Level EMS Registration
If you run or operate an EMS agency, the rule creates a new DEA registration category for EMS agencies and lets an agency obtain a single DEA registration for each State in which it operates instead of registering each separate location. The rule also requires an EMS agency to be registered in every State where it administers controlled substances.
Jump Bags and Carrying During Active Response
The rule allows EMS personnel to carry controlled substances on their person or in a jump bag while they are actively responding to an emergency, and such items are not treated as 'stored' during that active response. Controlled substances carried this way must be returned to approved secure storage when personnel are not engaged in a response.
Storage, Locking, and Vehicle Security Rules
The rule requires registered EMS agencies to store controlled substances in a securely locked, substantially constructed cabinet or safe or an automated dispensing machine, and EMS vehicles storing controlled substances must be locked when parked outside an enclosed registered or designated location unless personnel are present or at the scene of an emergency. Controlled substances must be kept in locked, non-removable storage when vehicles are unattended.
Recordkeeping ID Rule Made Flexible
If your EMS agency keeps records of controlled substance administrations, the rule requires records to reflect the last name or initials (not mandatory personal initials) of the person who administered the drug, the medical director or authorizing professional, the person who disposed of a drug, and any witness. The rule also requires EMS agencies to retain records of administrations, disposals, acquisitions, distributions, and deliveries and make them readily retrievable.
Licensing and Restock Flexibility
The rule requires EMS personnel who administer controlled substances to be licensed or certified by the State in which they practice. The rule also allows EMS vehicles to restock controlled substances at hospitals other than the hospital whose registration the EMS vehicle is using, provided the restock conditions and recordkeeping in Sec. 1307.14 are met.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-02284 — Fisheries of the Exclusive Economic Zone Off Alaska; Pacific Cod by Catcher Vessels Greater Than or Equal to 60 Feet (18.3 Meters) Length Overall Using Pot Gear in the Bering Sea and Aleutian Islands Management Area
Starting February 4, 2026, fishing for Pacific cod using pot gear is temporarily banned for catcher vessels 60 feet or longer in the Bering Sea and Aleutian Islands. This stop helps keep the 2026 catch limits from being broken, protecting fish stocks and the fishing industry. The closure lasts until September 1, 2026, so big boats need to plan their fishing carefully to avoid penalties.
Next: 2026-02290 — Reef Fish Fishery of the Gulf of America; 2026 Commercial Accountability Measure for Gulf of America Greater Amberjack
Fishermen who catch greater amberjack in the Gulf of America will face lower catch limits in 2026 because they caught too many fish in 2025. The government is cutting the allowed commercial catch by 8,184 pounds to help protect the amberjack population. This new rule starts February 5, 2026, and lasts through the end of the year, keeping the fishery healthy for the future.